Septerna
Develops oral small-molecule drugs for GPCR targets in endocrinology, immunology and metabolic disease
Highlights
- New on EvolcAdded 2026-11-13
About Septerna
Septerna is a biotechnology company that discovers and develops oral small-molecule drugs targeting G protein-coupled receptors (GPCRs). Its proprietary Native Complex Platform isolates and reconstitutes GPCRs outside cells, supports high-resolution 3D structure determination by cryogenic electron microscopy, and screens candidate molecules.
The company's wholly-owned pipeline is focused initially on endocrinology, immunology and inflammation, and metabolic diseases. Recent milestones include the selection of SEP-204 as a development candidate for Graves' disease and thyroid eye disease, and the initiation of a Phase 1 clinical trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism.
Jeffrey Finer, MD, PhD, is Chief Executive Officer and co-founder, and Robert Lefkowitz, MD, is among the scientific founders. Current job openings are in South San Francisco, California, covering pharmaceutical development, DMPK, clinical development, AI/ML for drug discovery, and portfolio management.
Product: Native Complex Platform for GPCR drug discovery and an internal pipeline of oral small-molecule drug candidates.
Jobs at Septerna
More biotech & pharma companies
Serif Biomedicines
Develops modified-DNA genetic medicines for treating and preventing diseaseShennon Biotechnologies
Develops T-cell engager cancer immunotherapies for solid tumors using a single-cell functional screening platformNew on EvolcSimtra BioPharma Solutions
Contract development and manufacturing of sterile injectable medicines for pharmaceutical and biopharmaceutical companiesSingular Genomics
High-throughput spatial multiomics platform (G4X) and sequencing services for researchers and clinical labsSpear Bio
Ultra-sensitive protein biomarker immunoassay kits and testing services for neuroscience researchers and cliniciansRemote-friendlyTarsus Pharmaceuticals
Biopharmaceutical company developing eye-care treatments; its FDA-approved XDEMVY treats Demodex blepharitis, an eyelid diseaseNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Gravity FormsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.